Dyslipidaemia, hypercoagulability and the metabolic syndrome

Curr Vasc Pharmacol. 2006 Jul;4(3):175-83. doi: 10.2174/157016106777698432.

Abstract

The metabolic syndrome is a clustering of risk factors including central obesity, insulin resistance, dyslipidaemia and hypertension. This syndrome is associated with increased risk of cardiovascular disease and is a common early abnormality in the development of type 2 diabetes. The pathogenesis of the syndrome has multiple origins. Obesity and sedentary lifestyle coupled with genetic factors interact to produce the syndrome. Here, we consider two components of the metabolic syndrome, dyslipidaemia and hypercoagulability.

Publication types

  • Review

MeSH terms

  • Adipose Tissue / metabolism
  • Adiposity
  • Animals
  • Aspirin / therapeutic use
  • Cardiovascular Diseases / blood
  • Cardiovascular Diseases / drug therapy
  • Cardiovascular Diseases / etiology*
  • Cardiovascular Diseases / metabolism
  • Cholesterol, HDL / blood
  • Clofibric Acid / therapeutic use
  • Dyslipidemias / blood
  • Dyslipidemias / complications*
  • Dyslipidemias / drug therapy
  • Dyslipidemias / metabolism
  • Factor VII / metabolism
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hypolipidemic Agents / therapeutic use
  • Inflammation Mediators / metabolism
  • Insulin Resistance
  • Life Style
  • Lipoproteins, LDL / blood
  • Metabolic Syndrome / blood
  • Metabolic Syndrome / complications*
  • Metabolic Syndrome / drug therapy
  • Metabolic Syndrome / metabolism
  • Obesity / blood
  • Obesity / complications
  • Obesity / drug therapy
  • Obesity / metabolism
  • Plasminogen Activator Inhibitor 1 / blood
  • Plasminogen Activator Inhibitor 1 / metabolism
  • Thrombophilia / blood
  • Thrombophilia / complications*
  • Thrombophilia / drug therapy
  • Thrombophilia / metabolism
  • Triglycerides / blood
  • von Willebrand Factor / metabolism

Substances

  • Cholesterol, HDL
  • Fibrinolytic Agents
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypolipidemic Agents
  • Inflammation Mediators
  • Lipoproteins, LDL
  • Plasminogen Activator Inhibitor 1
  • SERPINE1 protein, human
  • Triglycerides
  • von Willebrand Factor
  • Clofibric Acid
  • Factor VII
  • Aspirin